Enhance patient care

Our mission to improve a patient’s quality of life by enabling them to benefit from personal insights at the genomic level of their disease, could never be accomplished without the commitment from care providers that offer their knowledge, experience, and wholehearted support to patients and their respective needs and wishes.

Through innovative molecular diagnostic tools, we are determined to empower care providers by making more information on the patient’s disease available that allows for personalized treatment decision-making. Precision diagnostics holds great potential in addressing many current clinical unmet needs to ultimately improve patient outcomes in a value-based manner.

How our biomarker diagnostics can support you

As a company with the highest regard for quality, we are ISO13485 certified, and both our commercial assays: the Merlin™ test and SKY92, have been certified to meet regulatory approval requirements such as the European CE-IVD mark, demonstrating compliance with quality and safety standards.

Our diagnostic assays are developed to be both scientifically robust and clinically meaningful.

The Merlin™ test

The Merlin™ test is in-licensed from and co-developed with Mayo Clinic (USA). It is commercially available in the United States and Europe. Merlin uses the proprietary CP-GEP algorithm to identify cutaneous melanoma (skin cancer) patients at low risk of having nodal metastasis who could forgo an invasive surgery under general anesthetics.

SKY92

SKY92 is in-licensed from the Erasmus MC (Rotterdam, the Netherlands). It is commercially available in the United States and Europe. SKY92 calculates the risk of having an aggressive form of multiple myeloma (blood cancer) that might require a more intensive treatment regimen to increase the length of the remission.

0 +

collaborations

We have formed strong partnerships with renowned institutes like Mayo Clinic, Erasmus MC, and Imperial College London, collaborating in various stages of diagnostic development.

0 +

publications

With over 20 publications and growing our robust research contributes to the advancement of science, ultimately providing patients with better care.

dedicated R&D programs

Falcon (dermato-oncology), Panthera (hematology), and Delphia (infectious and inflammatory diseases) all focus on their respective disease areas to uncover and optimize the clinical pathway to the patient.

0 +

years of experience

With over 10 years of experience in molecular diagnostics, we lead innovation for personalized healthcare.

Partner with us

We believe that scientifically robust and clinically meaningful biomarkers should find their way to patients, therefore we don’t focus on one disease or group of diseases specifically. We encourage you to submit your biomarker discovery or your proposal to write a grant application with us. We are always open to new collaborations. Whether it regards collaborations to collect additional evidence on products already in our pipeline or collaborations outside our current R&D Programs.

Scroll to see more ›

Lab Operations Team

Belinda Dumee BASc

Director Lab Operations

Daphne Huigh MSc

Research Lab Manager

Dayanara Jacquin

Director of Operations

Deborah Bokx

Lab Technician

Lizanne Bosman BASc

Manager Lab Operations

Maria Rodriguez BSc

Clinical Laboratory Scientist

Monique van Steen-Luijcks

Lab Technician

Ricardo Sanna BSc

Senior Lab Technician, Equipment Subject Matter Expert

Sena Zümrütçü BASc

Senior Lab Technician

Tanner Hagelstrom

Laboratory Director (US)

Our trusted collaborations

What others have to say about us

"We are excited to partner with SkylineDx on the commercial availability of the Merlin™ test. This partnership marks an exciting moment in the journey to bring precision medicine and personalized healthcare to melanoma patients."

"As an investment and advisory firm for the Life Sciences industry, Novalis LifeSciences LLC funds and advises innovative companies to achieve their growth goals. SkylineDx is focused on their mission to provide precision diagnostics that result in significant improvements in patient care, through both scientific and commercial excellence. Novalis is excited to have the opportunity to provide SkylineDx with strategic guidance on its path to success."

"We have worked with the team at SkylineDx for many years on several research projects focused on advancing personalized care in skin cancer. Identifying patients who are at risk for more advanced disease. Our experience is that the combination of the research of both institutes and the clinical perspective are really the base of science that improves patient care. The work that we are committed to should lead to providing more reassurance to patients at low risk and early on identifying those who are at risk of developing distant metastasis and, therefore, require more intense management."

"We have been working with SkylineDx since 2019 and have extended our statement of work several times over the years. Through our collaboration, they have supported us in overcoming several challenges with their devoted and professional team. SkylineDx has shown that they deliver high-quality work and have proven their expertise in molecular diagnostics, which is essential for the development of novel and first-in-class immuno-modulatory antibodies for cancer therapies."